RESEARCH ARTICLE

Torquetenovirus in saliva: A potential biomarker for SARS-CoV-2 infection?

Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paiao, Andrea B. C. Ferraz, Ana C. Mamana, Noely E. Ferreira, Anderson V. de Paula, Alvina C. Felix, Camila M. Romano, Paulo H. Braz-Silva, Fabio E. Leal, Regina M. Z. Grespan, Ester C. Sabino, Silvia F. Costa, Steven S. Witkin

1 Faculdade de Medicina da Universidade de Sao Paulo-Laboratório de Investigacão em Virologia (LIM52)-Instituto de Medicina Tropical de Sao Paulo, Universidade de Sao Paulo, Sao Paulo, Brazil, 2 Faculdade de Medicina da Universidade Municipal de Sao Caetano do Sul, Sao Paulo, Brazil, 3 Faculdade de Odontologia da Universidade de Sao Paulo – Departamento de Estomatologia, Sao Paulo, Brazil, 4 Faculdade de Medicina da Universidade de Sao Paulo-Laboratório de Investigação Médica em Virologia (LIM46)-Instituto de Medicina Tropical de Sao Paulo, Sao Paulo, Brazil, 5 Faculdade de Medicina da Universidade de Sao Paulo-Laboratório de Investigação Médica em Virologia (LIM49)-Instituto de Medicina Tropical de Sao Paulo, Sao Paulo, Brazil, 6 Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York, United States of America

* These authors contributed equally to this work.
* tozetto@usp.br

Abstract

Torquetenovirus (TTV) is present in biological fluids from healthy individuals and measurement of its titer is used to assess immune status in individuals with chronic infections and after transplants. We assessed if the titer of TTV in saliva varied with the presence of SARS-CoV-2 in the nasopharynx and could be a marker of COVID-19 status. Saliva from 91 individuals positive for SARS-CoV-2 in nasal-oropharyngeal samples, and from 126 individuals who were SARS-CoV-2-negative, all with mild respiratory symptoms, were analyzed. Both groups were similar in age, gender, symptom duration and time after symptom initiation when saliva was collected. Titers of TTV and SARS-CoV-2 were assessed by gene amplification. Loss of smell (p = 0.0001) and fever (p = 0.0186) were more prevalent in SARS-CoV-2-positive individuals, while sore throat (p = 0.0001), fatigue (p = 0.0037) and diarrhea (p = 0.0475) were more frequent in the SARS-CoV-2 negative group. The saliva TTV and nasal-oropharyngeal SARS-CoV-2 titers were correlated (p = 0.0085). The TTV level decreased as symptoms resolved in the SARS-CoV-2 infected group (p = 0.0285) but remained unchanged in the SARS-CoV-2 negative controls. In SARS-CoV-2-positive subjects who provided 2–4 saliva samples and in which TTV was initially present, the TTV titer always decreased over time as symptoms resolved. We propose that sequential TTV measurement in saliva is potentially useful to assess the likelihood of symptom resolution in SARS-CoV-2-positive individuals and to predict prognosis.
Introduction

Torquetenovirus (TTV) is a small, single stranded DNA virus present in multiple body fluids of apparently healthy individuals [1, 2]. It is generally considered to be a non-pathogenic endogenous virus and is not associated with any known pathology. However, since its titer in body fluids varies with the local immune status, determination of the TTV titer has been shown to be a sensitive quantitative indicator of the likelihood of rejection following organ transplantations [3–5]. The higher the TTV titer the greater is the level of immune suppression. TTV measurement also has value outside of organ transplantation. Its detection and titer have been utilized as a marker of immune function in chronic diseases such as liver cirrhosis [6] or HIV [7].

TTV has been shown to be present in human saliva [8, 9]. In a patient who underwent an allogeneic hematopoietic stem cell transplant, detection of TTV was more frequent and the TTV titer was higher in saliva as opposed to plasma [9]. This led the authors to suggest that quantitation of TTV in saliva may be of value in predicting immunocompetence after engraftment [8].

The worldwide pandemic of Coronavirus disease 2019 (COVID-19) is due to infection by severe acute respiratory syndrome virus-2 (SARS-CoV-2) [10]. To our knowledge there is only a single study, a case report, on the association between the TTV titer and SARS-CoV-2 [11]. In a 42 year old male kidney transplant patient who exhibited only mild symptoms of COVID-19, his peripheral blood TTV titer was highest when SARS-CoV-2 was first detected in a nasopharyngeal swab. The TTV titer was greatly reduced when symptoms resolved and his nasopharyngeal swab became SARS-CoV-2-negative. The patient remained on immunosuppressive medication both at the onset and after resolved COVID-19. When the SARS-CoV-2 infection was resolved the extent of lymphopenia decreased and TTV proliferation was reduced. SARS-CoV-2 has been shown to contribute to lymphopenia [12, 13]. These observations suggest that measurement of the TTV titer may have value as a surrogate marker of SARS-CoV-2 infection.

In the present study we measured the TTV titer over time in saliva from mildly symptomatic individuals who were positive for SARS-CoV-2 in nasal-oropharyngeal samples. Controls were individuals with similar symptoms who were negative for SARS-CoV-2. We hypothesized that the salivary TTV titer in the SARS-CoV-2 patients would vary during the course of their disease and, thus, might be of value as a measurement of COVID-19 progression or resolution.

Materials and methods

Ethics, study design, setting and population

The study was approved by the local ethics committee: Comissão Nacional de Ética em Pesquisa do Ministério da Saúde do Brasil (CONEP), protocol No. CAAE 30419320.7.0000.0068, dated April, 18, 2020) and all subjects provided written informed consent. This observational, prospective study used a convenience samples from participants in The Corona São Caetano Program, a primary care initiative offering COVID-19 care to all residents of São Caetano do Sul, Brazil [14]. Briefly, residents with symptoms consistent with COVID-19 were encouraged to contact the Corona São Caetano platform via a website or by phone. Subjects were excluded from study if they presented symptoms related to an allergy or bacterial infection and/or used antibiotics or other medications in the two weeks prior to sample collection. All subjects from study have no underlying condition. The respondents were invited to complete an initial screening questionnaire that included information on type, onset and duration of symptoms. Those with symptoms consistent with COVID-19 were contacted by a medical student for...
further risk assessment. Individuals meeting pre-defined criteria for mild COVID-19 were offered a home visit in which a self-collected nasal-oropharyngeal swabs and a saliva sample were obtained for analysis. Samples were collected from May 5 to May 30, 2020.

**Sample collection**

Nasal-oropharyngeal samples were collected from both nostrils and the oropharynx using commercial flocked swabs with plastic applicators (Goodwood Medical Care Ltd., Jinzhou, China). Saliva samples were collected using a cotton pad device–Salivette™ (Sarstedt AG & CO. KG, Nümbrecht, Germany). To provide guidance on self-collection procedures, a link to an instructional video was sent to each participant before the home visit. Briefly, subjects were instructed to insert the swabs into both nostrils and the posterior region of the mouth and put all swabs into a tube containing a saline solution. For saliva collection, they were instructed to vigorously chew a cotton pad for one minute before its placement into a separate tube. Participants were instructed to avoid eating, drinking or toothbrushing at least one hour before the saliva collection. In accordance with the Corona São Caetano Program procedures, all samples were collected in the morning, immediately placed in a cool box (2–8˚C) and stored at 4˚C in a refrigerator until shipment to the lab that same afternoon by a specialized carrier. The date that the swabs were collected was noted. Several individuals positive for SARS-CoV-2 in their saliva were requested to collect additional saliva samples over a 30 day period, while those who tested negative were followed up in the primary health-care program. The patients were asked to contact the platform for a new consultation if they developed new symptoms.

**Analysis for SARS-CoV-2**

Nasal-oropharyngeal samples were handled according to laboratory biosafety guidelines. The specimens underwent RNA extraction by using the EasyMag® automatized extractor (NucliSENS® easyMag®, bioMérieux, Durham, NC), according to the manufacturer’s instructions. All samples were deemed suitable for amplification by RT-PCR based on analysis of the internal control consisting of primers and probe for the human Ribonuclease P gene (GenBank accession number NM_006413), as described [15]. Samples were then subjected to RT-PCR (RealStar® SARS-CoV-2 RT-PCR Kit 1.0, Altona Diagnostics) in order to provide a qualitative diagnosis for SARS-CoV-2. For in house absolute quantification by real-time polymerase chain reaction (qPCR), specific primers and probes for the E-gene and NP-gene of SARS-CoV2 were synthesized, as described previously [16, 17]. HPLC-purified oligonucleotides sequences of both genes of SARS-CoV-2 were synthesized as follows: E-gene -synthetic oligo (E): 5´ TTCG TATATTTGCAAGGACGATCCGACCGATACCGTATCGAAGCGCAGTAAGGATGGCTAGTGTATGCGTACG CTATTACATTATAACGTACCTGTCTGATA−3’ and NP-gene -synthetic oligo (HKU_NP): 5´− TTCGTCGAAGGTGTGACTTCCATGCGTAATCCGCAAAATTGACATGGCGTAAT CAGTTCTTTGCTGATTACTGATA−3’.

Standard curves with known amounts of the synthetic sequences were generated for qPCR by a methodology previously described [18, 19]. The in house assay was performed by using TaqMan™ Fast one virus master mix protocol (Thermo Fisher Scientific®, Austin, USA). The data were analyzed using QuantStudio Design & Analysis Software v.1.4.1. The range of detection of the E-gene was 3.5 to 10.1 log_{10} copies per mL, with an amplification efficiency value of 91.9% (slope of -3.5, y-intercept of 40.82, R2 of 0.99). For the NP-gene, the range of detection was 4.7 to 11.7 log_{10} copies per mL, with an amplification efficiency value of 98.0% (slope of -3.37, y-intercept of 39.65, R2 of 0.95). The lower limit of detection of the qPCR assay was 3,049 copies per ml (3.5 log_{10} copies per ml). The viral load data were based on the E-gene findings. The NP-gene analysis was used as a confirmatory test to verify the viral load.
TTV titer analysis

A cotton pad device—Salivette™ (Sarstedt AG & CO. KG, Nümbrecht, Germany) was used for saliva collection, according to the manufacturer’s instructions. The total DNA from salivary fluid was extracted and purified by using the EasyMag automatized platform (NucliSENS® easyMag® bioMérieux, Durham, NC). All DNA samples were deemed suitable for DNA amplification by PCR based on analysis of the internal control. For TTV detection in saliva, TTV-specific probe and primers were performed as previously described by Maggi et al [20]. A standard curve with known amounts of a synthetic DNA was performed for TTV absolute quantification by real-time polymerase chain reaction as previously described [21]. The TTV DNA amplification was based on the TaqMan™ Universal PCR master mix protocol (Thermo Fisher Scientific, Warrington, UK). The data were analyzed using QuantStudio Design & Analysis Software v.1.4.1. The range of detection of TTV in saliva was 1.6 to 7.4 log_{10} copies per ml. Positive and negative controls for TTV in saliva were obtained from samples stored in the repository at the Virology Laboratory (Institute of the Tropical Medicine of the Medicine School of the São Paulo University, Brazil). The lower limit of detection of the qPCR assay for TTV was 40 copies per ml (1.6 log_{10} copies/ml).

Statistics

Differences in discrete variables between individuals positive or negative for SARS-CoV-2 were analyzed by Fisher’s exact test. Continuous variables were analyzed by the Mann-Whitney test. Differences in the TTV titer over time was analyzed by the Kruskal-Wallis test. Correlations between TTV and SARS-CoV-2 titer were analyzed by the Spearman rank correlation test. A p value < 0.05 was considered significant.

Results

The characteristics of the study population are shown in Table 1. There was a small increased prevalence of females in both the 91 SARS-CoV-2- positive patients (54.9%) and the 126 negative subjects (61.1%). Mean age was comparable (42.9 years and 41.4 years) in positive and negative participants, respectively. Similarly, the median time (range) from symptom onset to resolution was 4 (1–10) days in the SARS-CoV-2-positives and 4 (1–30) days in the controls. None of these differences were significant (p > 0.05).

The frequency of specific symptoms manifested by individuals in both groups is described in Table 2. Most self-reported symptoms were comparable and independent of SARS-CoV-2 status. The prevalence of fever, designated as a temperature > 37.5°C (p = 0.0186) and loss of smell (p = 0.0001) were higher in SARS-CoV-2-positive subjects while a sore throat (p = 0.0001), fatigue (p = 0.037) and diarrhea (p = 0.0475) were more common in the negative controls. Among the COVID-19 patients, loss of smell was more frequent in men (78.0%) than in women (52.9%) (p = 0.0138). Fever was also more common in the male COVID-19 patients (56.1% versus 38.1% in females), but this did not reach statistical significance (p = 0.0773).

| Characteristic      | SARS-CoV-2 Positive (n = 91) | SARS-CoV-2 Negative (n = 126) | P value |
|---------------------|------------------------------|-------------------------------|---------|
| Gender              | Male No. samples (%)         | 41 (45.1)                     | 49 (38.9) | p > 0.05 |
|                     | Female No. samples (%)       | 50 (54.9)                     | 77 (61.1) | p > 0.05 |
| Age                 | Mean (Standard Deviation)    | 42.9 (16.3)                   | 41.4 (14.7) | p > 0.05 |
| Duration of symptoms| Median (range)               | 4 (1–10) days                 | 4 (1–30) days | p > 0.05 |

https://doi.org/10.1371/journal.pone.0256357.t001
TTV was identified in saliva from 54.9% of SARS-CoV-2-positive subjects and in 62.7% of the negative controls. Variations in the saliva TTV titer as a function of the time from symptom onset, utilizing a single sample from each subject, is summarized in Table 3. In the first 9 days after symptom initiation the median log$_{10}$ TTV titer/ml was relatively constant. However, starting on day 10 the TTV titer became greatly reduced in the SARS-CoV-2-positive subjects (p = 0.0285) but remained unchanged in the controls (p = 0.5255). In addition, the saliva TTV and nasal-oropharyngeal SARS-CoV-2 levels in the COVID-19-positive patients were correlated (p = 0.0085).

More than one saliva sample was available from 10 subjects. The decrease in TTV titer over time in these individuals is shown in Fig 1. In all cases, paralleling the findings in Table 3, there was a marked decrease in the TTV titer in individual patients as symptoms resolved and SARS-CoV-2 levels decreased.

**Discussion**

TTV was detected in saliva from individuals who were positive for SARS-CoV-2 in their nasopharynx, and there was a significant decrease in the TTV titer as their respiratory symptoms resolved and their SARS-CoV-2 level decreased. Thus, in parallel to results of studies on TTV detection in transplant patients and in those with chronic infections, it is reasonable to propose

| Table 2. Specific symptoms in individuals in association with nasopharynx SARS-CoV-2 status. |
|---------------------------------------------------------------|
| **Symptom**          | **SARS-CoV-2 Positive (n = 91)** | **SARS-CoV-2 Negative (n = 126)** | **P value** |
|----------------------|---------------------------------|----------------------------------|-------------|
| Shortness of breath  | 1 (1.1%)                        | 1 (0.7%)                         | p>0.05      |
| Fever                | 49 (54.6%)                      | 47 (37.3%)                       | 0.0186      |
| Cough                | 68 (74.7%)                      | 92 (73.0%)                       | p>0.05      |
| Sore throat          | 40 (44.0%)                      | 89 (70.6%)                       | 0.0001      |
| Nasal congestion     | 58 (63.7%)                      | 72 (57.1%)                       | p>0.05      |
| Runny nose           | 44 (48.4%)                      | 74 (58.7%)                       | p>0.05      |
| Headache             | 68 (74.7%)                      | 98 (77.8%)                       | p>0.05      |
| Fatigue              | 49 (53.8%)                      | 93 (73.8%)                       | 0.0037      |
| Weakness             | 41 (45.1%)                      | 65 (51.6%)                       | p>0.05      |
| Anorexia             | 39 (42.9%)                      | 59 (46.8%)                       | p>0.05      |
| Myalgia              | 63 (69.2%)                      | 85 (67.5%)                       | p>0.05      |
| Arthralgia           | 43 (47.3%)                      | 57 (45.2%)                       | p>0.05      |
| Diarrhea             | 14 (15.4%)                      | 34 (27.0%)                       | 0.0475      |
| Nausea               | 23 (25.3%)                      | 33 (26.2%)                       | p>0.05      |
| Vomiting             | 5 (5.5%)                        | 10 (7.9%)                        | p>0.05      |
| Loss of smell        | 68 (74.7%)                      | 46 (36.5%)                       | 0.0001      |
| Loss of taste        | 38 (41.8%)                      | 38 (30.2%)                       | 0.0617      |

TTV was identified in saliva from 54.9% of SARS-CoV-2-positive subjects and in 62.7% of the negative controls. Variations in the saliva TTV titer as a function of the time from symptom onset, utilizing a single sample from each subject, is summarized in Table 3. In the first 9 days after symptom initiation the median log$_{10}$ TTV titer/ml was relatively constant. However, starting on day 10 the TTV titer became greatly reduced in the SARS-CoV-2-positive subjects (p = 0.0285) but remained unchanged in the controls (p = 0.5255). In addition, the saliva TTV and nasal-oropharyngeal SARS-CoV-2 levels in the COVID-19-positive patients were correlated (p = 0.0085).

More than one saliva sample was available from 10 subjects. The decrease in TTV titer over time in these individuals is shown in Fig 1. In all cases, paralleling the findings in Table 3, there was a marked decrease in the TTV titer in individual patients as symptoms resolved and SARS-CoV-2 levels decreased.

**Discussion**

TTV was detected in saliva from individuals who were positive for SARS-CoV-2 in their nasopharynx, and there was a significant decrease in the TTV titer as their respiratory symptoms resolved and their SARS-CoV-2 level decreased. Thus, in parallel to results of studies on TTV detection in transplant patients and in those with chronic infections, it is reasonable to propose

| Table 3. Torquetenovirus titer in saliva as a function of days from symptom initiation in relation to SARS-CoV-2 status. |
|---------------------------------------------------------------|
| **Days** | **SARS-CoV-2 positive** | **SARS-CoV-2 negative** |
|-----------|-------------------------|-------------------------|
|           | No. Samples | Median log$_{10}$ TTV titer/ml (range) | No. samples | Median log$_{10}$ TTV titer/ml (range) |
| 3–5       | 27          | 3.3 (0, 6.1)              | 54          | 3.6 (0, 7.4)              |
| 6–7       | 19          | 2.0 (0, 6.2)              | 26          | 4.4 (0, 7.3)              |
| 8–9       | 16          | 3.8 (0, 5.7)              | 20          | 3.6 (0, 7.4)              |
| 10–16     | 20          | 0.0 (0, 5.2)              | 21          | 3.9 (0, 6.2)              |
| >16       | 8           | 0.0 (0, 2.5)              | 5           | 5.1 (0, 5.8)              |
that the TTV titer in saliva is a surrogate biomarker for immune system activation in the nasopharynx. An initial high TTV titer at symptom initiation in SARS-CoV-2-infected patients is indicative of a localized SARS-CoV-2-mediated immune suppression, while a subsequent decrease in TTV parallel to the resolution of symptoms and the SARS-CoV-2 infection denotes an elevation in local immunity. The finding of a strong correlation between the salivary TTV titer and the nasopharyngeal SARS-CoV2 titer adds further support to this hypothesis.

In the present study it was difficult to differentiate between individuals who were positive or negative for SARS-CoV-2 on the basis of symptoms. A marked exception was a self-reported loss of smell. This was very highly correlated with detection of SARS-CoV-2, consistent with findings from other studies (reviewed in ref. [22]). The higher prevalence of a loss in smell in male COVID-19 patients is consistent with studies suggesting that symptoms of SARS-CoV-2 infection may be more severe in males [23].

Strengths of the present study include the collection of saliva and nasal-oropharyngeal samples from individuals with similar symptoms seen at a single center and in whom SARS-CoV-2 status was unknown. All samples were tested for TTV and SARS-CoV-2 by the same group of investigators who were blinded to all clinical data. The paired analysis of patients subsequently diagnosed with COVID-19 with a comparable non-infected control group provides added reliability to data interpretation. This study has several limitations. We do not have measurements of any immune mediators in the saliva samples. Therefore, our proposed mechanism for the decrease in TTV titer with symptom resolution in the COVID-19 patients, i.e., a

![Diagram](https://doi.org/10.1371/journal.pone.0256357.g001)
reduction in immune suppression, requires further verification. An alternate explanation of our findings is that the observed change in salivary TTV level was merely an indicator of the presence or resolution of a mild respiratory tract infection and was unrelated to SARS-CoV-2. Other viruses [24], including different coronavirus species [25], may also have been present in the nasopharynx of our study population. Thus, the possible influence of viral co-infections on SARS-CoV-2-related salivary TTV levels remains undetermined. We would stress, however, that the uniform responses in the SARS-CoV-2 positive and negative patients suggest that any influence of other co-infections is likely to be relatively minor. A parallel diminution in TTV titer over time after resolution of respiratory symptoms was not observed in the SARS-CoV-2 negative individuals. This strongly suggests that immune alterations associated with a mild respiratory tract infection are insufficient to have a noticeable influence on TTV levels in saliva. Lastly, despite the apparent consistency of the findings, the use of saliva samples from different subjects to create a timeline of TTV changes, rather than using samples from the same individuals, is not ideal.

In conclusion, we propose that measurement of the saliva TTV level over time in individuals positive for SARS-CoV-2 may be of value in ascertaining variations in local immune status and as predictors of prognosis.

Acknowledgments
We thank the staff of the Laboratório de Investigação Médica em Virologia (LIM52)—Instituto de Medicina Tropical de Sao Paulo—Faculdade de Medicina da Universidade de Sao Paulo for technical support.

Author Contributions
Conceptualization: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Andrea B. C. Ferraz, Paulo H. Braz-Silva, Fabio E. Leal, Ester C. Sabino, Silvia F. Costa, Steven S. Witkin.
Data curation: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Heuder G. O. Paiao, Ana C. Mamana, Noely E. Ferreira, Camila M. Romano, Steven S. Witkin.
Formal analysis: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paiao, Andrea B. C. Ferraz, Noely E. Ferreira, Anderson V. de Paula, Camila M. Romano, Steven S. Witkin.
Funding acquisition: Maria C. Mendes-Correa, Ester C. Sabino.
Investigation: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paiao, Andrea B. C. Ferraz, Ana C. Mamana, Noely E. Ferreira, Anderson V. de Paula, Alvina C. Felix, Fabio E. Leal, Regina M. Z. Grespan, Steven S. Witkin.
Methodology: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paiao, Andrea B. C. Ferraz, Ana C. Mamana, Noely E. Ferreira, Anderson V. de Paula, Alvina C. Felix, Camila M. Romano, Paulo H. Braz-Silva, Steven S. Witkin.
Project administration: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Ester C. Sabino, Silvia F. Costa, Steven S. Witkin.
Resources: Maria C. Mendes-Correa, Heuder G. O. Paiao, Andrea B. C. Ferraz, Ester C. Sabino, Steven S. Witkin.
Software: Andrea B. C. Ferraz.
Supervision: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Fabio E. Leal, Regina M. Z. Grespan, Silvia F. Costa, Steven S. Witkin.

Validation: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paião, Ana C. Mamana, Noely E. Ferreira, Paulo H. Braz-Silva, Steven S. Witkin.

Visualization: Steven S. Witkin.

Writing – original draft: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Steven S. Witkin.

Writing – review & editing: Maria C. Mendes-Correa, Tania Regina Tozetto-Mendoza, Wilton S. Freire, Heuder G. O. Paiao, Andrea B. C. Ferraz, Ana C. Mamana, Noely E. Ferreira, Anderson V. de Paula, Alvina C. Felix, Camila M. Romano, Paulo H. Braz-Silva, Fabio E. Leal, Regina M. Z. Grespan, Ester C. Sabino, Silvia F. Costa, Steven S. Witkin.

References

1. Biagini P. Classification of TTV and related viruses (anelloviruses). Curr Top Microbial Immunol 2009; 331:21–33.
2. Ross RS, Viazov S, Runde V, Schaefer UW, Roggendorf M. Detection of TT virus DNA in specimens other than blood. J Clin Virol 1999; 13:181–4. https://doi.org/10.1016/s1386-6532(99)00015-3 PMID: 10443794
3. Fernandez-Ruiz M. Torque Teno virus load as a surrogate marker for the net state of immunosuppression: the beneficial side of the virome. Am J Transplant 2020; 20:1963–4. https://doi.org/10.1111/ajt.15872 PMID: 32189426
4. Pradier A, Masouridi-Levrat S, Bosshard C, Dantin C, Vu D-L, Zanella M-C, et al. Toque Teno virus as a potential biomarker for complications and survival after allogeneic hematopoietic stem cell transplantation. Front Immunol 2020; 11:998.
5. Focosi D, Macera L, Pistello M, Maggi F. Torquetenovirus (TTV) viremia correlates with intensity of maintenance immunosuppression in adult orthotopic liver transplantation. J Infect Dis 2014; 210:667–8. https://doi.org/10.1093/infdis/jiu209 PMID: 24688876
6. Mrzljak A, Vilbic-Caviek T. Torque teno viruses in liver diseases and after liver transplantation. World J Transplant 2020; 10:291–6. https://doi.org/10.5500/wjt.v10.i11.291 PMID: 33312890
7. Dibiaggi M, Zara F, Sacchi P, Bruno R, Mazzucco M, Poma R, et al. Transfusion-transmitted virus infection in HIV-1 seropositive patients. Clin Microbiol Infect 2000; 6:246–50. https://doi.org/10.1046/j.1469-0691.2000.00069.x PMID: 11168120
8. Torres AE, Talaya A, Gimenez E, Pinana JL, Hernandez-Boluda J, Focosi D, et al. Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. J Med Virol 2018; 90:1438–43. https://doi.org/10.1002/jmv.25218 PMID: 29724787
9. Naganuma M, Tominaga N, Miyamura T, Soda A, Moriiuchi M, Moriiuchi H. TT virus prevalence, viral loads and genotypic variability in saliva from healthy Japanese children. Acta Paediatr 2008; 97:1686–90. https://doi.org/10.1111/j.1651-2227.2008.00962.x PMID: 18671690
10. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020; 10:587269. https://doi.org/10.3389/fcimb.2020.587269 PMID: 33324574
11. Querido S, Caica R, Weigert A, Francisco D, Adragao T, Pessanha MA, et al. Kinetics of torque teno virus DNA load in a recent kidney transplant recipient with mild SARS-CoV-2 infection and a failed antibody response. Transpl Infect Dis 2020; e13524. https://doi.org/10.1111/tid.13524 PMID: 33226684
12. Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395:514–23. https://doi.org/10.1016/S0140-6736(20)30154-9 PMID: 31986261
13. Lombardi A, Trombetta E, Cattaneo A, Castelli V, Palomba E, Tirone M, et al. Early phases of COVID-19 are characterized by a reduction in lymphocyte populations and the presence of atypical monocytes. Front Immunol 2020; 11:560330. https://doi.org/10.3389/fimmu.2020.560330 PMID: 33362757
14. Leal FE, Mendes-Correa MC, Buss LF et al. Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona Sao Caetano primary care programme: a prospective cohort study. BMJ Open 2021; 11:e042745. https://doi.org/10.1136/bmjopen-2020-042745 PMID: 33436471
15. Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 2004; 10(2):311–316. https://doi.org/10.3201/eid1002.030759 PMID: 15030703

16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020 Jan; 25(3):200045.

17. Chu DKW, Pan Y, Cheng SMS, Hui KP, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem 2020; 66(4):549–5. https://doi.org/10.1093/clinchem/hvaa029 PMID: 32031583.

18. Tourinho RS, de Almeida CR, Lemos AS, Gardinali NR, Vieira YR, Schmidt-Chanasit J, et al. Application of Synthetic Standard Curves for Absolute Quantification of Hepatitis A and E by Real-Time PCR, J Genet Genome Res 2015; 2:013.

19. Lima LR, Silva AP, Schmidt-Chanasit J, Paula VS. Diagnosis of human herpes virus 1 and 2 (HHV-1 and HHV-2): use of a synthetic standard curve for absolute quantification by real time polymerase chain reaction. Mem Inst Oswaldo Cruz. 2017; 112(3):220–3. https://doi.org/10.1590/0074-02760160354 PMID: 28225902

20. Maggi F, Pistello M, Vatteroni M, Presciutti S, Marchi S, Isola P, et al. Dynamics of persistent TT virus infection, as determined in patients treated with alpha interferon for concomitant hepatitis C virus infection J Virol 2001; 75:11999–2004. https://doi.org/10.1128/JVI.75.24.11999-12004.2001 PMID: 11711590

21. Tozetto-Mendoza TR, Bongiovanni AM, Minis E, Linhares IM, Boeister A, Freire WS, et al. Torquetenovirus titer in vaginal secretions from pregnant and postpartum women: Association with absence of Lactobacillus crispatus and levels of lactic acid and matrix metalloproteinase-8. Reprod Sci 2020; 27:2075–81. https://doi.org/10.1007/s43032-020-00227-1 PMID: 32944879

22. Printza A, Constantindis J. The role of self-reported smell and taste disorders in suspected COVID-19. Eur Arch Otorhinolaryngol 2020; 227:2625–30.

23. Gebhard C, Regiyz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences 2020; 11:29. https://doi.org/10.1186/s13293-020-00304-9 PMID: 32459096

24. Prasetyo AA, Desyardi MN, Tanamas J, Suradi, Revioni, Harsini, et al. Respiratory viruses and Torque teno virus in adults with acute respiratory infections. Intervirology 2015; 58:57–68. https://doi.org/10.1159/000369211 PMID: 25890989

25. Cabeca TK, Passos AM, Granato C, Bellei N. Human coronavirus occurrence in different populations of Sao Paulo: A comprehensive nine-year study using a pan-coronavirus RT-PCR assay. Braz J Microbiol 2013; 44:335–9. https://doi.org/10.1590/S1517-83822013000100049 PMID: 24159325